Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space

  • HC Wainwright initiated coverage on LAVA Therapeutics NV LVTX with a Buy rating and a price target of $9.
  • The company is focused on developing Gammabodies for cancer treatments.
  • According to the analyst, the Gammabody platform could deliver superior anti-tumor activity by leveraging γδ T cells' advantages, such as broad antigen recognition, distinguishing healthy tissues from the tumor, and activating proinflammatory immune systems cascades. 
  • The lead candidate, LAVA-051, is being evaluated in a Phase 1/2a study in multiple blood cancer settings.
  • Initial Phase 1 data showed a favorable safety profile and early signs of clinical activity.
  • Additional dose-escalation data is expected in 2H22, and initial Phase 2a data from the expansion cohorts in 1H23. 
  • Related: LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen.
  • LAVA is also evaluating LAVA-1207 in a Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) therapy, with initial data expected in 4Q22/1Q23. 
  • "We believe Gammabody could be a game changer in the bispecific T cell engagers space. We currently project LAVA to generate risk-adjusted peak revenues of $391 million in 2032, growing from $4 million in 2026," the analyst writes.
  • Price Action: LVTX shares are down 0.20% at $4.25 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CarePrice TargetInitiationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!